✨ Your Portfolio is fetched and updated from zerodha.
Mid Pharmaceuticals

Aurobindo Pharma Ltd.

AUROPHARMA

Market Cap
₹63,667 Cr.
P/E
18.26

Aurobindo Pharma Ltd.

  • Aurobindo Pharma
  • Abbott India
  • Alkem Laboratories
  • TJI Pharma
FAQs on Aurobindo Pharma Ltd. Shareprice

Aurobindo Pharma has given lower returns compared to its competitors.
Aurobindo Pharma has grown at ~26.84% over the last 2yrs while peers have grown at a median rate of 36.49%

Aurobindo Pharma is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA.
Latest PE of Aurobindo Pharma is 18.26, while 3 year average PE is 16.81.
Also latest EV/EBITDA of Aurobindo Pharma is 9.67 while 3yr average is 10.27.

View FAQ's On Business
Growth Table
  • Aurobindo Pharma Ltd.
  • Abbott India
  • Alkem Laboratories
Balance Sheet
  • Aurobindo Pharma Ltd.
  • Abbott India
  • Alkem Laboratories
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Aurobindo Pharma Ltd.
  • Abbott India
  • Alkem Laboratories
Cash Flow
  • Aurobindo Pharma Ltd.
  • Abbott India
  • Alkem Laboratories
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Aurobindo Pharma Ltd.
  • Abbott India
  • Alkem Laboratories
Quarterly Results
  • Aurobindo Pharma Ltd.
  • Abbott India
  • Alkem Laboratories
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF
FAQs on Aurobindo Pharma Ltd. Financials

Balance sheet of Aurobindo Pharma is strong.
It shouldn't have solvency or liquidity issues.

Yes, The net debt of Aurobindo Pharma is increasing.
Latest net debt of Aurobindo Pharma is -₹293.81 Crs as of Mar-25.
This is greater than Mar-24 when it was -₹6,241.12 Crs.

Yes, profit is increasing.
The profit of Aurobindo Pharma is ₹3,515 Crs for TTM, ₹3,173 Crs for Mar 2024 and ₹1,928 Crs for Mar 2023.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Aurobindo Pharma latest dividend payout ratio is 8.31% and 3yr average dividend payout ratio is 12.45%

Companies resources are allocated to majorly productive assets like Plant & Machinery

View FAQ's On Shareholding
Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech